Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Acorda Therapeutics Inc. ACOR

Acorda Therapeutics Inc is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda uses scientific, clinical, and commercial expertise in neurology as strategic points of access in additional nervous system markets, including stroke, Parkinson's disease, and epilepsy. The company does not operate separate lines of business with respect to any of its products or product candidates. All of its net product revenue is derived from the United States.


Recent & Breaking News (NDAQ:ACOR)

Acorda Therapeutics to Present at Two Investor Conferences in May

Business Wire April 29, 2016

Acorda Provides Financial and Pipeline Update for First Quarter 2016

Business Wire April 28, 2016

Acorda Announces Results from Phase 2b Clinical Trial of CVT-301 for Treatment of OFF Periods in Parkinson's Disease Published in Movement Disorders

Business Wire April 20, 2016

Completion of Acorda Therapeutics' Voluntary Tender Offer for All of the Issued and Outstanding Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies Corp. and Matters Related Thereto

Business Wire April 18, 2016

Acorda to Host Conference Call to Discuss First Quarter 2016 on April 28, 2016

Business Wire April 14, 2016

Final Results of Acorda Therapeutics' Voluntary Tender Offer for All of the Issued and Outstanding Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies Corp. and Commencement of a Subsequent Offer Period

Business Wire April 13, 2016

Acorda Therapeutics Announces Preliminary Tender Offer Results and Acceptance of the Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies Corp. Tendered in Tender Offer

Business Wire April 11, 2016

Phase 2b Data on Inhaled Levodopa CVT-301 Featured in Invited Science Session at American Academy of Neurology (AAN) Annual Meeting

Business Wire April 7, 2016

Acorda Therapeutics Supplements the Tender Offer Document Relating to the Voluntary Public Tender Offer for All of the Issued and Outstanding Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies Corp. on 22 March 2016

Business Wire March 22, 2016

Acorda Wins Federal Circuit Appeal Allowing AMPYRA® Patent Litigation to Continue in Delaware District Court

Business Wire March 21, 2016

Acorda Therapeutics Supplements Tender Offer Document Relating to the Voluntary Public Tender Offer for All of the Issued and Outstanding Shares, American Depositary Shares, Stock Options, Share Units and Warrants in Biotie Therapies on 18 March 2016

Business Wire March 18, 2016

Acorda Announces Patent Trials and Appeal Board (PTAB) Institutes IPRs of AMPYRA Patents

Business Wire March 11, 2016

Acorda Has Filed Tender Offer Document Relating to Public Tender Offer For Biotie Therapies with Finnish Financial Supervisory Authority

Business Wire March 3, 2016

Acorda Therapeutics to Present at Two Investor Conferences in March

Business Wire March 1, 2016

Acorda Announces Expiration of the Hart-Scott-Rodino Waiting Period for Its Tender Offer for Biotie Therapies

Press Releases February 17, 2016

TomTom Telematics named Frost & Sullivan 2016 European Fleet Telematics Company of the Year

Press Releases February 17, 2016

Eutelsat Communications First Half 2015-2016 Results

Press Releases February 17, 2016

EUTELSAT COMMUNICATIONS : RÉSULTATS DU PREMIER SEMESTRE 2015-2016

Press Releases February 17, 2016

Acorda Provides Financial and Pipeline Update for Fourth Quarter and Year End 2015

Business Wire February 11, 2016

Acorda Therapeutics to Present at Two Investor Conferences in February

Business Wire February 4, 2016